Achieve Life Sciences (ACHV) completed the US Food and Drug Administration long-term exposure requirement for cytisinicline, a treatment designed to help people quit smoking, with no safety concerns identified.
More than 300 participants completed six months of cumulative cytisinicline treatment in the ORCA-OL clinical trial, the company said Tuesday in a statement.
The company remains on track for the planned New Drug Application submission in Q2.
The company's shares rose 6.2% in recent Tuesday trading.
Price: 3.77, Change: +0.22, Percent Change: +6.20
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。